Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Mecasermin (Increlex) vs Sermorelin
An educational, source-based comparison of Mecasermin (Increlex) and Sermorelin — how each peptide works, what it's researched for, and what to know before going deeper.
Recombinant human insulin-like growth factor-1 (rhIGF-1) that binds IGF-1 receptors to promote linear growth in children with severe primary IGF-1 deficiency or GH gene deletion with anti-GH antibodies.
- Severe primary IGF-1 deficiency
- Growth failure with GH gene deletion and neutralizing GH antibodies
- • FDA-approved.
- • Hypoglycemia — must be taken with food.
- • Tonsillar hypertrophy, intracranial hypertension reported.
A synthetic 29-amino-acid analog representing the active fragment of endogenous GHRH. Stimulates the pituitary to release GH in a physiologic, pulsatile pattern. Previously FDA-approved (Geref) for pediatric GH deficiency diagnosis before discontinuation for commercial reasons.
- Adult GH deficiency
- Pediatric short stature (historical)
- Sleep quality and body composition in aging
- • No longer commercially available as an FDA-approved drug; available via compounding.
- • Requires physician oversight.
- • Banned in competitive sport.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Mecasermin (Increlex) | Mecasermin in severe primary IGFD | JCEM | 2007 | Improved height velocity over multi-year follow-up. |
| Sermorelin | Sermorelin in adult growth hormone deficiency | Endocrine Practice | 2010 | Reviewed efficacy on body composition, energy, and sleep markers. |
Side-effect & safety grid
- FDA-approved.
- Hypoglycemia — must be taken with food.
- Tonsillar hypertrophy, intracranial hypertension reported.
- No longer commercially available as an FDA-approved drug; available via compounding.
- Requires physician oversight.
- Banned in competitive sport.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Mecasermin (Increlex) vs Sermorelin — Key differences
- Class: Mecasermin (Increlex) is classified as IGF-1 · Endocrine, while Sermorelin is Growth Hormone Axis.
- Primary research focus: Mecasermin (Increlex) — severe primary igf-1 deficiency; Sermorelin — adult gh deficiency.
- Tag: FDA-Approved · Endocrine vs Growth hormone.